Lunch Symposium (I)

Targeted Therapies In Neuroendocrine Tumors

12:20 - 13:00, L & B Cafe (醫圖咖啡廳)

Department of Oncology
Taipei Veterans General Hospital, Taipei, Taiwan

Speaker

Associate Professor

Ming-Huang Chen
MD, PhD

陳明晃 副教授

President of Taiwan NET Society
Professor of Surgery, General Surgery, Chang Gung Memorial Hospital, Chang Gung University, Linkou, Taiwan

Moderator

Professor

Tsann-Long Hwang

MD, FACS

黃燦龍 教授

Abstract - Targeted therapies in neuroendocrine tumors

     Neuroendocrine tumors are a group of heterogeneous malignancies arising from neuroendocrine cells throughout the body. Data from population-based registries indicate that 51% of neuroendocrine tumors arise from the gastrointestinal (GI) tract, 27% from the lungs, and 6% from the pancreas. Clinically, neuroendocrine tumors are regarded as functional if they are associated with symptoms of hormonal hypersecretion, or non-functional if they are not associated with these symptoms. Although carcinoid syndrome is classically associated with metastatic, well-differentiated neuroendocrine tumors of the small intestine, an analysis of National Comprehensive Cancer Centre database showed that most (74%) neuroendocrine tumors are nonfunctional. 

     Advanced neuroendocrine tumors are incurable in nearly all cases. The somatostatin analogue, approved for control of hormonal syndrome, has been shown to delay disease progression in patients with neuroendocrine tumors. Targeted therapies such as everolimus and sunitinib are approved for advanced pancreatic neuroendocrine tumors.
In addition, everolimus showed robust anti-tumor activity with acceptable tolerability across a broad range of neuroendocrine tumors, including those arising from the GI tract and lung (RADIANT 4 study). Other treatment strategies, including chemotherapy (E2211 trial) and peptide receptor radiotherapy (NETTLER study) are also approved for advanced well differentiated NETs.

 

       Recently, several potential targeted therapies were developed in well differentiated NETs and showed promising results in phase 2 clinical trials. NETs have emerged due to an improved understanding of the molecular mechanisms responsible for tumor  development and progression. 
 

Sponsored by

台大醫院消化外科國際論壇暨林天祐學術研討會

NTUH International Forum of Digestive Surgery & TY Lin Symposium

2020 台大醫院一般外科忘年會

2020 NTUH General Surgery Celebration Event

Multidisciplinary approach in pancreatic cancer

What

2020一般外科國際論壇暨林天祐學術研討會

When

January 18th, 2020

Where

​台大醫學院 104 講堂

Contact Us

To learn more, don’t hesitate to get in touch

  • White Facebook Icon
  • White Instagram Icon
  • White Twitter Icon
  • White LinkedIn Icon

© 2023 by TIC. Proudly created with Wix.com